Maryland State Retirement & Pension System lifted its position in shares of Colgate-Palmolive Company (NYSE:CL – Free Report) by 13.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 48,672 shares of the company’s stock after acquiring an additional 5,756 shares during the period. Maryland State Retirement & Pension System’s holdings in Colgate-Palmolive were worth $4,153,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of the company. State Street Corp boosted its stake in Colgate-Palmolive by 97.4% during the 2nd quarter. State Street Corp now owns 94,195,992 shares of the company’s stock valued at $8,635,889,000 after purchasing an additional 46,476,510 shares during the period. Bank of New York Mellon Corp grew its position in Colgate-Palmolive by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 13,532,417 shares of the company’s stock worth $1,240,652,000 after purchasing an additional 1,010,872 shares during the last quarter. First Eagle Investment Management LLC increased its stake in shares of Colgate-Palmolive by 1.1% in the second quarter. First Eagle Investment Management LLC now owns 8,205,699 shares of the company’s stock valued at $752,298,000 after purchasing an additional 88,917 shares during the period. Amundi increased its stake in shares of Colgate-Palmolive by 19.9% in the second quarter. Amundi now owns 6,218,257 shares of the company’s stock valued at $570,090,000 after purchasing an additional 1,033,918 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Colgate-Palmolive in the second quarter valued at approximately $567,483,000. Institutional investors and hedge funds own 80.41% of the company’s stock.
Colgate-Palmolive News Summary
Investors following CL have been watching these news items:
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.91 from $3.85, close to the $3.92 consensus, and nudged its FY2027 and FY2028 forecasts higher to $4.06 and $4.38, respectively. These revisions suggest modest confidence in longer-term earnings growth. Zacks Research Has Bullish Forecast for CL FY2026 Earnings
- Neutral Sentiment: A comparison with Kimberly-Clark highlighted Colgate-Palmolive’s leading global oral-care position and its pet-nutrition business as potential growth diversifiers, but the article did not report a new company-specific catalyst. Colgate-Palmolive vs. Kimberly-Clark
- Negative Sentiment: A Colgate-Palmolive executive vice president sold $401,677 worth of company shares. Insider sales can weigh on sentiment, although a single transaction does not necessarily indicate a change in the company’s outlook. Insider Selling: Colgate-Palmolive EVP Sells Stock
Insider Transactions at Colgate-Palmolive
In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 19,938 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $98.74, for a total transaction of $1,968,678.12. Following the completion of the transaction, the chief operating officer directly owned 9,111 shares of the company’s stock, valued at approximately $899,620.14. This trade represents a 68.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Noel Wallace sold 20,000 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $100.26, for a total value of $2,005,200.00. Following the transaction, the chief executive officer directly owned 359,700 shares of the company’s stock, valued at approximately $36,063,522. The trade was a 5.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 77,414 shares of company stock valued at $7,613,786. 0.43% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Colgate-Palmolive in a report on Thursday, August 13th. Morgan Stanley increased their price objective on Colgate-Palmolive from $104.00 to $111.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. Bank of America raised their target price on Colgate-Palmolive from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Barclays raised their target price on Colgate-Palmolive from $87.00 to $95.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 3rd. Finally, BNP Paribas Exane reaffirmed an “outperform” rating and set a $108.00 target price (up from $97.00) on shares of Colgate-Palmolive in a research note on Monday, November 2nd. Thirteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.22.
Check Out Our Latest Analysis on Colgate-Palmolive
Colgate-Palmolive Stock Down 0.1%
Colgate-Palmolive stock opened at $99.62 on Monday. The stock has a market cap of $79.19 billion, a price-to-earnings ratio of 39.07, a PEG ratio of 4.51 and a beta of 0.31. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 11.23. The company’s 50-day moving average price is $90.94 and its two-hundred day moving average price is $90.29. Colgate-Palmolive Company has a 52 week low of $75.96 and a 52 week high of $101.18.
Colgate-Palmolive (NYSE:CL – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.34 billion. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. Colgate-Palmolive’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.91 EPS. On average, analysts expect that Colgate-Palmolive Company will post 3.92 EPS for the current fiscal year.
Colgate-Palmolive Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, November 13th. Investors of record on Tuesday, October 20th were issued a dividend of $0.53 per share. The ex-dividend date of this dividend was Tuesday, October 20th. This represents a $2.12 annualized dividend and a yield of 2.1%. Colgate-Palmolive’s payout ratio is presently 83.14%.
About Colgate-Palmolive
Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company’s best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill’s Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.
Featured Stories
- Five stocks we like better than Colgate-Palmolive
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL – Free Report).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.
